Episode 10. Most pharma brands in India don't own a factory — they partner with a WHO-GMP certified contract manufacturer and focus on building their brand. This episode covers what Janus Biotech's third party manufacturing actually offers: a wide product range across tablets, capsules, injectables, syrups, nutraceuticals, and herbal formulations, flexible batch sizes, full DCGI-approved documentation, in-house packaging design, and a transparent process from formulation to final dispatch. Also explore Janus Biotech's ethical monopoly PCD franchise and full product range. Earlier episodes covered choosing a niacinamide serum manufacturer, the future of Vonoprazan PCD through 2027, Janus Biotech as a company, whether Vonoprazan PCD is right for you, HP kit and Domperidone combinations, the Vonoprazan PCD opportunity, Vonoprazan as a treatment, and the rise of niacinamide serum manufacturing. 👉 https://janus.co.in/third-party-manufacturing/

Episode 9. Most skincare brands choose a niacinamide serum manufacturer based on price — and most of them regret it. This episode covers what actually matters when evaluating a supplier: formulation expertise, certifications, stability testing standards, MOQ flexibility, and communication. Based on Janus Biotech's guide to choosing the best niacinamide serum supplier — covering everything from R&D capability and GMP compliance to private label and custom formulation services. Also explore Janus Biotech's niacinamide serum manufacturing and contract manufacturing services. Earlier episodes covered the future of Vonoprazan PCD business through 2027, Janus Biotech as a company, whether Vonoprazan PCD is right for you, HP kit and Domperidone combinations, the Vonoprazan PCD opportunity, Vonoprazan as a treatment, and the rise of niacinamide serum manufacturing in India. 👉 https://janus.co.in/how-to-choose-the-best-niacinamide-serum-supplier/

Episode 8. India's GERD market is projected to reach ₹2,245 crore by 2033, and Vonoprazan is capturing a growing share of it — backed by Torrent, Lupin, Dr Reddy's, Zydus, and Mankind all launching their own brands. This episode covers the future of Vonoprazan PCD pharma business in India through 2027 — falling prices, growing combination products, and why tier-2 and tier-3 cities are where the real opportunity lies for franchise partners right now. Also explore Janus Biotech's Vonoprazan PCD, HP kit and Domperidone guide and the Vonoprazan 10mg and 20mg product range. Earlier episodes covered Janus Biotech as a company, whether Vonoprazan PCD is right for you, HP kit and Domperidone combinations, the Vonoprazan PCD opportunity, Vonoprazan as a treatment, and the rise of niacinamide serum manufacturing. 👉 https://janus.co.in/future-of-vonoprazan-pcd-pharma-business-in-india/

Episode 7. Six episodes in and we've been deep in Vonoprazan — today we step back and look at Janus Biotech as a whole. From a single pharmacy in 1957 to one of North India's fastest growing pharma companies, with 3500+ products, 1500+ business partners, and 17 specialized divisions covering gastro, cardiac, gynecology, derma, pediatrics, nutraceuticals, orthopedics and more. This episode covers what that range means for franchise partners and why a multi-division company changes the math on long-term business growth. Explore ethical monopoly marketing and PCD franchise, contract manufacturing, and the full product range at Janus Biotech. Earlier episodes covered Vonoprazan as a treatment, the Vonoprazan PCD opportunity, HP kit and Domperidone combinations, whether Vonoprazan PCD is right for you, and India's GERD market through 2027.
👉 https://janus.co.in/

Vonoprazan is reshaping how India treats acid reflux, working faster and controlling night-time acid breakthrough better than older PPIs like pantoprazole or omeprazole — which is why major players from Torrent to Mankind have launched their own versions within months of each other. In this episode, we look at where the Vonoprazan PCD opportunity is headed through 2027, from falling prices as exclusivity fades to the rise of H. pylori combination products, and why tier 2 and tier 3 cities are set to drive most of the growth. This continues what we've built up in earlier episodes — starting with what makes Vonoprazan the next-gen acid reflux treatment, then the Vonoprazan PCD opportunity nobody's talking about, the Vonoprazan HP kit and Domperidone combination, and whether Vonoprazan PCD is the right franchise for you. For the full market breakdown behind this episode, read Janus Biotech's guide to the future of Vonoprazan PCD pharma business in India.

Episode 5. Vonoprazan PCD franchise is gaining traction — but is it the right move for your business? This episode breaks down the honest case: chronic repeat prescriptions, early mover advantage in a growing category, and a versatile product range covering GERD, nausea, and H. pylori eradication. Full details in Janus Biotech's Vonoprazan PCD, HP kit and Domperidone guide. If you're just joining us, Episode 2 covered Vonoprazan as a next-gen acid reflux treatment, Episode 3 broke down the Vonoprazan PCD opportunity, and Episode 4 explored the HP kit and Domperidone combinations. Episode 1 covered the rise of niacinamide serum manufacturing in India. https://janus.co.in/vonoprazan-pcd-hp-kit-domperidone-guide/

Episode 4. We go deeper into the Vonoprazan product range — covering two combinations that are gaining serious traction with doctors right now. The Vonoprazan HP kit and Vonoprazan Domperidone guide by Janus Biotech covers H. pylori eradication therapy, chronic GERD management, and why these combinations make a strong case for any gastro franchise portfolio. We also cover the Vonoprazan 10mg and 20mg tablet range available through Janus Biotech's PCD franchise model. If you're just joining us, Episode 2 covered Vonoprazan as a next-gen acid reflux treatment and Episode 3 broke down the Vonoprazan PCD franchise opportunity in detail.

Episode 3. Vonoprazan is already gaining ground with doctors — but the real opportunity is on the distribution side. This episode breaks down why a Vonoprazan PCD pharma franchise makes business sense right now, from repeat demand driven by chronic GERD patients to monopoly rights and strong profit margins. We also cover the HP kit for H. pylori therapy and the Vonoprazan Domperidone combination — two products that round out a solid gastro portfolio. You can explore Vonoprazan 10mg and 20mg tablets directly on the Janus Biotech product page. If you missed the earlier episodes, Episode 2 covered Vonoprazan as a next-gen acid reflux treatment and Episode 1 explored the rise of niacinamide serum manufacturing in India.

In Episode 2 of The Janus Pharma Insights, we explore Vonoprazan — a potassium-competitive acid blocker (P-CAB) offering fast, lasting relief for GERD, reflux esophagitis, and peptic ulcers. We look at why it's gaining traction with healthcare providers and how Janus Biotech supplies high-grade Vonoprazan 10 mg and 20 mg tablets to distributors and pharmacies across India. Looking for a reliable supply partner? Visit janus.co.in to learn more.
🔗 Read more: https://janus.co.in/product/vonoprazan-20-mg-10mg/

In this episode of The Janus Pharma Insights, we explore the rise of niacinamide serum manufacturing in India and why skincare brands are rapidly investing in niacinamide-based products. From growing consumer awareness and dermatologist-backed skincare trends to private label cosmetic manufacturing and third-party serum production, this podcast discusses the factors driving demand in the Indian skincare industry.

Listen to insights on niacinamide serum manufacturing, cosmetic manufacturing in India, private label skincare products, serum formulation trends, and the growing business opportunities in the skincare market. This episode also highlights how skincare brands are partnering with experienced cosmetic manufacturers for scalable and quality-focused serum production.